Printed from https://ideas.repec.org/s/spr/pharme.html
Content
September 2025, Volume 43, Issue 9
- 999-1000 Bayesian Meta-Analysis: A Practical Introduction
by Christopher S. Hollenbeak - 1001-1045 Global Assessment of Health Utilities Associated with Pneumococcal Disease in Children—Targeted Literature Reviews
by Min Huang & Jipan Xie & Hela Romdhani & Yan Song & Sun Lee & Daisy Liu & Elamin Elbasha & Salini Mohanty & Donna Rowen & Matthew S. Kelly - 1047-1063 An Updated Systematic Literature Review of the Economic Costs of Loneliness and Social Isolation and the Cost Effectiveness of Interventions
by Lidia Engel & Muhammad Fikru Rizal & Sharon Clifford & Jan Faller & Michelle H. Lim & Long Khanh-Dao Le & Mary Lou Chatterton & Cathrine Mihalopoulos - 1065-1082 The Psychometric Performance of Generic Preference-Based Measures in Informal Carers: A Systematic Review of Validation Studies
by Jan Faller & Valeriia Sokolova & Yared Belete Belay & Gang Chen & Cathrine Mihalopoulos & Brendan Mulhern & Lidia Engel - 1083-1108 Are Economic Evaluations of Task Shifting Too Narrow in Focus? A Rapid Review
by Peter Murphy & Susan Griffin & Helen Fulbright & Simon Walker - 1109-1122 Health Care Resource Utilization and Costs Associated with US Medicaid Sobriety Restrictions on Direct-Acting Antivirals for Hepatitis C Virus: A Retrospective Claims Database Analysis
by Michelle T. Martin & Krithika Rajagopalan & Dilip Makhija & Fatema Turkistani & Caroline Burk & Marvin Rock & Alice Hsiao & Nancy Reau - 1123-1133 Inequalities in Quality-Adjusted Life Expectancy in Australia by Educational Attainment
by Sheridan E. Rodda & Melanie Lloyd & Jennifer Welsh & Jedidiah Morton & Rosemary Korda & Zanfina Ademi - 1135-1145 Innovation Headroom for a Highly Accurate PD-L1 Companion Diagnostic in Non-small Cell Lung Cancer
by Toluwase Akinsoji & Nick Dragojlovic & Cécile Darviot & Michel Meunier & Mark Harrison & Larry D. Lynd - 1147-1160 Key Considerations for Assessing Real-World Comparative Effectiveness in the Context of the Drug Price Negotiation Program: A Case Study of Pembrolizumab
by Antal T. Zemplenyi & Nai-Chia Chen & Kelly E. Anderson & Blythe Adamson & Michael J. DiStefano & Kavita V. Nair & Robert B. McQueen - 1161-1161 Correction: A Framework for Using Cost‑effectiveness Analysis to Support Pricing and Reimbursement Decisions for New Pharmaceuticals in a Context of Evolving Treatments, Prices, and Evidence
by Beth Woods & Alfredo Palacios & Mark Sculpher - 1163-1163 Correction: Exploring the Economic Burden of Pulmonary Arterial Hypertension and Its Relation to Disease Severity and Treatment Escalation: A Systematic Literature Review
by Gautam Ramani & Vishal Bali & Heather Black & Danny Bond & Ina Zile & Ashley C. Humphries & Dominik Lautsch
August 2025, Volume 43, Issue 8
- 845-848 When Evidence Falls Short—Belzutifan for Treating Tumours Associated with von Hippel-Lindau Disease: An External Assessment Group Perspective on a NICE Single Technology Appraisal
by Isaac Corro Ramos & Susan O’Meara & Mubarak Patel & Lisa Stirk & Jiongyu Chen & Xiaoyu Tian & Nigel Armstrong - 849-858 Under-reporting of Validation Efforts for Health Economic Models Persists Despite the Availability of Validation Tools: A Systematic Review
by Katharina Abraham & Isaac Corro Ramos & C. Louwrens Braal & Talitha Feenstra & Anne Kleijburg & George A. K. Voorn & Carin Uyl-de Groot - 859-877 The Use of EQ-5D in the Middle East and North Africa Region: A Systematic Literature Review
by Abeer Al Rabayah & Sibylle Puntscher & Fatima Al Sayah & Razan Sawalha & Elly Stolk & Judit Simon & Michael Drummond & Uwe Siebert - 879-936 The Evolving Landscape of Discrete Choice Experiments in Health Economics: A Systematic Review
by Sven Petrus Henricus Nouwens & Stella Maria Marceta & Michael Bui & Daisy Maria Alberta Hendrika Dijk & Catharina Gerarda Maria Groothuis-Oudshoorn & Jorien Veldwijk & Janine Astrid Til & Esther Wilhelmina Bekker-Grob - 937-953 Validation of the Cancer-Specific Preference-Based Measure EORTC QLU-C10D against the Generic Instruments EQ-5D-5L and SF-6Dv2 in a Prospectively Collected Sample of Patients with Cancer in Austria and France
by Micha J. Pilz & Simone Seyringer & Virginie Nerich & Madeleine T. King & Richard Norman & Eva M. Gamper - 955-968 Cost-Effectiveness of a Digital Leakage Notification System (Heylo™) for People with Ileostomies or Colostomies in the United Kingdom
by Esben Bo Boisen & Matthew Cawson & Lasse de Fries Jensen & Stuart Mealing & Naomi Hest - 969-985 Societal Versus Healthcare Perspectives on the Cost Effectiveness of Ocrelizumab for Treatment of Primary Progressive Multiple Sclerosis in Aotearoa New Zealand
by Richard J. Milne & Carsten Schousboe & Julie A. Campbell & John Mottershead - 987-997 Does the Informal Carer Identification Method Matter? Evidence from Self-Declaration and Time Diary Approaches
by Sean Urwin & Charles Smith & Matt Sutton
July 2025, Volume 43, Issue 7
- 691-710 A Framework for Reliable, Transparent, and Reproducible Population-Adjusted Indirect Comparisons
by K. Jack Ishak & Conor Chandler & Fei Fei Liu & Sven Klijn - 711-721 Cost-Effectiveness Analysis Methods Used in Evaluations of Treatment for Cystic Fibrosis: A Scoping Review
by Dominique Seo & David C. Young & Eberechukwu Onukwugha & T. Joseph Mattingly - 723-740 How do Health State Values Differ When Respondents Consider Adults Versus Children Living in Those States? A Systematic Review
by Ashwini De Silva & Alexander van Heusden & Zhongyu Lang & Nancy Devlin & Richard Norman & Kim Dalziel & Tessa Peasgood & Tianxin Pan - 741-760 Exploring the Economic Burden of Pulmonary Arterial Hypertension and Its Relation to Disease Severity and Treatment Escalation: A Systematic Literature Review
by Gautam Ramani & Vishal Bali & Heather Black & Danny Bond & Ina Zile & Ashley C. Humphries & Dominik Lautsch - 761-764 Anchoring the Hemophilia Joint Health Score for Conventional Value Assessment in the Care of People Living with Severe Hemophilia A
by Satoko Ito & Manraj Sra & George Goshua - 765-778 A Hemophilia Joint Health Score-Based Model for the Economic Evaluation of Hemophilia A Prophylaxis Interventions
by Sam Hirniak & Andrea N. Edginton & Alfonso Iorio & William W. L. Wong - 779-791 The Potential Health Economic Value of Adding Magnetomotive Ultrasound to Current Diagnostic Methods for Detecting Lymph Node Metastases in Rectal Cancer
by Emelie Andersson & Ulrika Axelsson & Carl-Fredrik Rönnow & Henrik Thorlacius & Linda Persson & Adam Fridhammar - 793-803 Defining Biological and Clinical Plausibility: The DICSA Framework for Protocolized Assessment in Survival Extrapolations Across Therapeutic Areas
by Bart Heeg & Dawn Lee & Jane Adam & Maarten Postma & Mario Ouwens - 805-817 Cost-Effectiveness of Adjuvant Alectinib Versus Chemotherapy for Patients with Resectable, ALK-positive Non-small Cell Lung Cancer in Canada
by Nick Jovanoski & Sarah Vaselenak & Andrew Hogan & Jasmine Turki & Quincy Chu - 819-833 Do the Age of Children and Parental Status Matter in Valuing the Child Health Utility 9D (CHU9D)?
by Xiuqin Xiong & Li Huang & Natalie Carvalho & Kim Dalziel & Nancy Devlin - 835-837 Comment on “Examining Consistency Across NICE Single Technology Appraisals: A Review of Appraisals for Paroxysmal Nocturnal Haemoglobinuria”
by Benjamin Farrar & Daniel Gladwell & Matthew Woods - 839-840 Reply to Comment on “Examining Consistency Across NICE Single Technology Appraisals: A Review of Appraisals for Paroxysmal Nocturnal Haemoglobinuria”
by Daniel Gallacher - 841-844 Correction: Health-Related Quality-of-Life Outcomes of Very Preterm or Very Low Birth Weight Adults: Evidence From an Individual Participant Data Meta-Analysis
by Corneliu Bolbocean & Sylvia Pal & Stef Buuren & Peter J. Anderson & Peter Bartmann & Nicole Baumann & Jeanie L. Y. Cheong & Brian A. Darlow & Lex W. Doyle & Kari Anne I. Evensen & John Horwood & Marit S. Indredavik & Samantha Johnson & Neil Marlow & Marina Mendonça & Yanyan Ni & Dieter Wolke & Lianne Woodward & Erik Verrips & Stavros Petrou
June 2025, Volume 43, Issue 6
- 597-600 Using AI in the Economic Evaluation of AI-Based Health Technologies
by Salah Ghabri - 601-616 A Review of Heterogeneity in Comparative Economic Analysis, with Specific Considerations for the Decentralized US Setting and Patient-Centered Care
by Michael S. Willis & Andreas Nilsson & Cheryl A. Neslusan - 617-627 What are the Revealed and Stated Population Preferences for Environmental Sustainability in Healthcare? A Scoping Review
by Charlotte Desterbecq & Mark Harrison & Sandy Tubeuf - 629-629 Correction: What are the Revealed and Stated Population Preferences for Environmental Sustainability in Healthcare? A Scoping Review
by Charlotte Desterbecq & Mark Harrison & Sandy Tubeuf - 631-646 Economic Evaluation of Interventions to Reduce Antimicrobial Resistance: A Systematic Literature Review of Methods
by Kristina Aluzaite & Marta O. Soares & Catherine Hewitt & Julie Robotham & Chris Painter & Beth Woods - 647-650 Artificial Intelligence as a New Research Ally? Performing AI-Assisted Systematic Literature Reviews in Health Economics
by Sietse Mossel & Martijn Johan Oude-Wolcherink & Rafael Emilio Feria Cardet & Lioe-Fee Geus-Oei & Dennis Vriens & Hendrik Koffijberg & Sopany Saing - 651-664 Market and Non-Market Productivity Losses Associated with Invasive Meningococcal Disease in the USA
by Hiral Anil Shah & Ginita Jutlla & Oscar Herrera-Restrepo & Jonathan Graham & Mei Grace & Shah Alam Khan & Elise Kuylen & Shahina Begum & Frederik Verelst & Zeki Kocaata - 665-675 Making Composite Time Trade-Off Sensitive for Worse-than-Dead Health States
by Michał Jakubczyk & Bram Roudijk & Stefan A. Lipman & Peep Stalmeier - 677-689 The Monetary Value of a Statistical Life in the Context of Atherosclerotic Cardiovascular Disease
by Jorge-Eduardo Martínez-Pérez & Fernando-Ignacio Sánchez-Martínez & José-María Abellán-Perpiñán & Domingo Pascual-Figal
May 2025, Volume 43, Issue 5
- 469-472 Uncertainty in Matching-Adjusted Indirect Comparisons Using Real-World Evidence: Evidence Assessment Group Perspective
by Cyril Onwuelazu Uteh & Eugenie Evelynne Johnson & Tomos Robinson & Najmeh Moradi & Alex Inskip & Fiona R. Beyer & Katie Thomson & Gurdeep S. Sagoo - 473-481 A Taxonomy for Assessing Whether HRQoL Value Sets Are Obsolete
by Richard Norman & Bram Roudijk & Marcel Jonker & Elly Stolk & Saskia Knies & Raoh-Fang Pwu & Ciaran O’Neill & Kirsten Howard & Nancy Devlin - 483-497 Towards Recommendations for Cost-Effectiveness Analysis of Predictive, Prognostic, and Serial Biomarker Tests in Oncology
by Astrid Kramer & Lucas F. Schaik & Daan Broek & Gerrit A. Meijer & Iñaki Gutierrez Ibarluzea & Lorea Galnares Cordero & Remond J. A. Fijneman & Marjolijn J. L. Ligtenberg & Ed Schuuring & Wim H. Harten & Veerle M. H. Coupé & Valesca P. Retèl - 499-508 Examining Consistency Across NICE Single Technology Appraisals: A Review of Appraisals for Paroxysmal Nocturnal Haemoglobinuria
by Jeremiah Donoghue & Matthew Youngs & Alex Reeve & Krishna Vydyula & Natalia Kunst & Roochi Trikha & Daniel Gallacher - 509-520 Prognostic Testing for Prostate Cancer—A Cost-Effectiveness Analysis Comparing a Prostatype P-Score Biomarker Approach to Standard Clinical Practice
by Adam Fridhammar & Oskar Frisell & Karin Wahlberg & Emelie Berglund & Pontus Röbeck & Sofie Persson - 521-553 Acceptance of Evidence Transfer Within German Early Benefit Assessment of New Drugs for Pediatric and Adolescents Target Populations
by Georgia Pick & Dirk Müller & Charalabos-Markos Dintsios - 555-567 EQ-5D-5L or EQ-HWB-S: Which is the Better Instrument for Capturing Spillover Effects in Parental Carers of Children with COVID-19?
by Wenjing Zhou & Bo Ding & Jan Busschbach & Michael Herdman & Zhihao Yang & Yanming Lu - 569-582 Cost-Effectiveness Analysis of Nirsevimab for Preventing Respiratory Syncytial Virus-Related Lower Respiratory Tract Disease in Dutch Infants: An Analysis Including All-Infant Protection
by Florian Zeevat & Simon Pol & Alexia Kieffer & Maarten J. Postma & Cornelis Boersma - 583-594 Innovative Payment Models for Sickle-Cell Disease Gene Therapies in Medicaid: Leveraging Real-World Data and Insights from CMMI’s Gene Therapy Access Model
by Antal Zemplenyi & Jim Leonard & Garth C. Wright & Michael J. DiStefano & Kavita Nair & Kelly E. Anderson & R. Brett McQueen - 595-596 Correction: De Novo Cost‑Effectiveness Model Framework for Nonalcoholic Steatohepatitis—Modeling Approach and Validation
by Peter Gal & Gyorgyi Feldmajer & Margarida Augusto & Ray Gani & Emma Hook & Ash Bullement & Zoe Philips & Inger Smith
April 2025, Volume 43, Issue 4
- 363-373 A Framework for Using Cost-effectiveness Analysis to Support Pricing and Reimbursement Decisions for New Pharmaceuticals in a Context of Evolving Treatments, Prices, and Evidence
by Beth Woods & Alfredo Palacios & Mark Sculpher - 375-388 Projections of Public Spending on Pharmaceuticals: A Review of Methods
by Irina Odnoletkova & Patrice X. Chalon & Stephan Devriese & Irina Cleemput - 389-402 How Does Bereavement Affect the Health-Related Quality of Life of Household Members Who Do and Do Not Provide Unpaid Care? Difference-in-Differences Analyses Using the UK Household Longitudinal Survey
by Becky Pennington & Mónica Hernández Alava & Mark Strong - 403-414 Value of Innovative Multiple Myeloma Treatments from Patient and Healthcare Provider Perspectives: Evidence from a Discrete Choice Experiment
by Sakil Syeed & Chia Jie Tan & Amandeep Godara & Kyna Gooden & Derek Tang & Samantha Slaff & Yu-Hsuan Shih & Surachat Ngorsuraches & Nathorn Chaiyakunapruk - 415-427 Value-Based Indication-Specific Pricing and Weighted-Average Pricing: Estimated Price and Cost Savings for Cancer Drugs
by Daniel Tobias Michaeli & Thomas Michaeli - 429-440 Cost Effectiveness of Exclusionary EGFR Testing for Taiwanese Patients Newly Diagnosed with Advanced Lung Adenocarcinoma
by Huang-Tz Ou & Jui-Hung Tsai & Yi-Lin Chen & Tzu-I. Wu & Li-Jun Chen & Szu-Chun Yang - 441-452 Home Urine Dipstick Screening for Bladder and Kidney Cancer in High-Risk Populations in England: A Microsimulation Study of Long-Term Impact and Cost-Effectiveness
by Olena Mandrik & Chloe Thomas & Edifofon Akpan & James W. F. Catto & Jim Chilcott - 453-467 Examination of Methods to Estimate Productivity Losses in an Economic Evaluation: Using Foodborne Illness as a Case Study
by Kathleen Manipis & Paula Cronin & Deborah Street & Jody Church & Rosalie Viney & Stephen Goodall
March 2025, Volume 43, Issue 3
- 243-247 Application of Multi-level Network Meta-Regression in the NICE Technology Appraisal of Quizartinib for Induction, Consolidation and Maintenance Treatment of Newly Diagnosed FLT3-ITD-Positive Acute Myeloid Leukaemia: An External Assessment Group Perspective
by Sarah J. Nevitt & David M. Phillippo & Robert Hodgson & Nicky J. Welton & Sofia Dias - 249-269 Economic Evaluations of Non-Pharmacological Interventions for Treating Disorders of Gut-Brain Interaction: A Scoping Review
by Anton Pak & Madeline O’Grady & Gerald Holtmann & Ayesha Shah & Haitham Tuffaha - 271-282 Cost Effectiveness of Tremelimumab Plus Durvalumab for Unresectable Hepatocellular Carcinoma in the USA
by Xiaomo Xiong & Jeff Jianfei Guo - 283-296 Unravelling the Association Between Uncertainties in Model-based Economic Analysis and Funding Recommendations of Medicines in Australia
by Qunfei Chen & Martin Hoyle & Varinder Jeet & Yuanyuan Gu & Kompal Sinha & Bonny Parkinson - 297-310 A Multistate Model Incorporating Relative Survival Extrapolation and Mixed Time Scales for Health Technology Assessment
by Enoch Yi-Tung Chen & Paul W. Dickman & Mark S. Clements - 311-329 Public Health Impact of Introducing a Pentavalent Vaccine Against Invasive Meningococcal Disease in the United States
by Hiral Anil Shah & Ginita Jutlla & Oscar Herrera-Restrepo & Jonathan Graham & Katherine A. Hicks & Justin Carrico & Mei Grace & Diana E. Clements & Cindy Burman & Woo-Yun Sohn & Elise Kuylen & Shahina Begum & Zeki Kocaata - 331-349 Immediate Versus 5-Year Risk-Guided Initiation of Treatment for Primary Prevention of Cardiovascular Disease for Australians Aged 40 Years: A Health Economic Analysis
by Jedidiah I. Morton & Danny Liew & Gerald F. Watts & Sophia Zoungas & Stephen J. Nicholls & Christopher M. Reid & Zanfina Ademi - 351-361 Cost-Effectiveness of Capivasertib as a Second-Line Therapy for Advanced Breast Cancer
by Trang T. H. Nguyen & Shweta Mital
February 2025, Volume 43, Issue 2
- 123-131 The Use of Real-World Data for Estimating Relative Treatment Effects in NICE Health Technology Assessment Submissions: A Review
by Yoojung Che & Stephen Duffield & Manuel Gomes - 133-151 A Systematic Literature Review of Modelling Approaches to Evaluate the Cost Effectiveness of PET/CT for Therapy Response Monitoring in Oncology
by Sietse Mossel & Rafael Emilio Feria Cardet & Lioe-Fee Geus-Oei & Dennis Vriens & Hendrik Koffijberg & Sopany Saing - 153-169 Costs of Care in Relation to Alzheimer’s Disease Severity in Sweden: A National Registry-Based Cohort Study
by Sandar Aye & Oskar Frisell & Henrik Zetterberg & Tobias Borgh Skillbäck & Silke Kern & Maria Eriksdotter & Emil Aho & Xin Xia & Bengt Winblad & Anders Wimo & Linus Jönsson - 171-176 Measuring Effectiveness Based on Patient Experience (Instead of QALYs) in US Value Assessments
by Maksat Jumamyradov & Benjamin M. Craig - 177-189 Recurrence of Cardiovascular Events After an Acute Myocardial Infarction in Patients with Multivessel Disease and Associated Healthcare Costs: A German Claims Data Analysis
by Alexandra Starry & Nils Picker & Jonathan Galduf & Ulf Maywald & Axel Dittmar & Stefan G. Spitzer - 191-207 Value-Based Healthcare in Practice: IDEATE, a Collaboration to Design and Test an Outcomes-Based Agreement for a Medicine in Wales
by Jessica R. Burton & Kate Halsby & Graciela Sáinz Fuente & Jonathan Pearson-Stuttard & Rebecca Sloan & Thomas Porter & Gareth John & Andrew Warburton & Jennifer Selby & Gail Povey & Ruhe Chowdhury & Catherine Bale & Mark Davies & Emma Clifton-Brown & Hamish Laing - 209-221 Comparison of EQ-5D-Y-3L Utility Scores Using Nine Country-Specific Value Sets in Chinese Adolescents
by Ya’nan Wu & Yanjiao Xu & Zhao Shi & Junchao Feng & Zhihao Yang & Zhuxin Mao & Lei Dou & Shunping Li - 223-239 Estimation of Transition Probabilities from a Large Cohort (> 6000) of Australians Living with Multiple Sclerosis (MS) for Changing Disability Severity Classifications, MS Phenotype, and Disease-Modifying Therapy Classifications
by Julie A. Campbell & Glen J. Henson & Valery Fuh Ngwa & Hasnat Ahmad & Bruce V. Taylor & Ingrid Mei & Andrew J. Palmer - 241-241 Correction: Estimation of Transition Probabilities from a Large Cohort (> 6000) of Australians Living with Multiple Sclerosis (MS) for Changing Disability Severity Classifications, MS Phenotype, and Disease-Modifying Therapy Classifications
by Julie A. Campbell & Glen J. Henson & Valery Fuh Ngwa & Hasnat Ahmad & Bruce V. Taylor & Ingrid Mei & Andrew J. Palmer
January 2025, Volume 43, Issue 1
- 5-29 Design and Features of Pricing and Payment Schemes for Health Technologies: A Scoping Review and a Proposal for a Flexible Need-Driven Classification
by Vittoria Ardito & Oriana Ciani & Michael Drummond - 31-43 Comparative Analysis of Traditional and Pharmacometric-Based Pharmacoeconomic Modeling in the Cost-Utility Evaluation of Sunitinib Therapy
by Maddalena Centanni & Janine Nijhuis & Mats O. Karlsson & Lena E. Friberg - 45-52 How Much Better is Faster? Empirical Tests of QALY Assumptions in Health-Outcome Sequences
by F. Reed Johnson & John J. Sheehan & Semra Ozdemir & Matthew Wallace & Jui-Chen Yang - 53-66 Managed Entry Agreements for High-Cost, One-Off Potentially Curative Therapies: A Framework and Calculation Tool to Determine Their Suitability
by Marcelien H. E. Callenbach & Rick A. Vreman & Christine Leopold & Aukje K. Mantel-Teeuwisse & Wim G. Goettsch - 67-82 The Impact of Tocilizumab Coverage on Health Equity for Inpatients with COVID-19 in the USA: A Distributional Cost-Effectiveness Analysis
by Stacey Kowal & Katherine L. Rosettie - 83-91 Economic Burden Associated with Pulmonary Arterial Hypertension in the United States
by Anna Watzker & Adnan Alsumali & Christine Ferro & Gabriela Dieguez & Clare Park & Dominik Lautsch & Karim El-Kersh - 93-107 Universal Health Coverage of Opioid Agonist Treatment in Norway: An Equity-Adjusted Economic Evaluation
by Prayash Chaudhary & Lars Thore Fadnes & Steinar Fosse & Fatemeh Chalabianloo & Kjell Arne Johansson - 109-122 Estimating the Incremental Cost Per QALY Produced by the Spanish NHS: A Fixed-Effect Econometric Approach
by Laura Vallejo-Torres
December 2024, Volume 42, Issue 12
- 1301-1315 Incorporating Complexity and System Dynamics into Economic Modelling for Mental Health Policy and Planning
by Paul Crosland & Deborah A. Marshall & Seyed Hossein Hosseini & Nicholas Ho & Catherine Vacher & Adam Skinner & Kim-Huong Nguyen & Frank Iorfino & Sebastian Rosenberg & Yun Ju Christine Song & Apostolos Tsiachristas & Kristen Tran & Jo-An Occhipinti & Ian B. Hickie - 1317-1327 MPES-R: Multi-Parameter Evidence Synthesis in R for Survival Extrapolation—A Tutorial
by Ash Bullement & Mark Edmondson-Jones & Patricia Guyot & Nicky J. Welton & Gianluca Baio & Matthew Stevenson & Nicholas R. Latimer - 1329-1343 Cost and Cost Effectiveness of Treatments for Psoriatic Arthritis: An Updated Systematic Literature Review
by Ippazio Cosimo Antonazzo & Giorgia Gribaudo & Adriano Vecchia & Pietro Ferrara & Alexandra Piraino & Paolo Angelo Cortesi & Lorenzo Giovanni Mantovani - 1345-1357 Effects and Costs of Hepatitis C Virus Elimination for the Whole Population in China: A Modelling Study
by Meiyu Wu & Jing Ma & Sini Li & Shuxia Qin & Chongqing Tan & Ouyang Xie & Andong Li & Aaron G. Lim & Xiaomin Wan - 1359-1371 Different Models, Same Results: Considerations When Choosing Between Approaches to Model Cost Effectiveness of Chimeric-Antigen Receptor T-Cell Therapy Versus Standard of Care
by Amy Gye & Richard Abreu Lourenco & Stephen Goodall - 1373-1394 Evidence Following Conditional NICE Technology Appraisal Recommendations: A Critical Analysis of Methods, Quality and Risk of Bias
by Yankier Pijeira Perez & Dyfrig A. Hughes - 1395-1412 An Evaluation of an Algorithm for the Selection of Flexible Survival Models for Cancer Immunotherapies: Pass or Fail?
by Nicholas R. Latimer & Kurt Taylor & Anthony J. Hatswell & Sophia Ho & Gabriel Okorogheye & Clara Chen & Inkyu Kim & John Borrill & David Bertwistle - 1413-1425 Valuation of the EORTC Quality of Life Utility Core 10 Dimensions (QLU-C10D) in a Multi-ethnic Asian Setting: How Does Having Cancer Matter?
by Mihir Gandhi & Ravindran Kanesvaran & Mohamad Farid Bin Harunal Rashid & Dawn Qingqing Chong & Wen-Yee Chay & Rachel Lee-Yin Tan & Richard Norman & Madeleine T. King & Nan Luo
November 2024, Volume 42, Issue 11
- 1177-1179 Using Cure Modelling for Cost Effectiveness in the NICE Technology Appraisal of Polatuzumab Vedotin in Combination for Untreated Diffuse Large B Cell Lymphoma: An External Assessment Group Perspective
by Keith Cooper & Emma Maund & Marcia Tomie Takahashi & Jonathan Shepherd - 1181-1196 Treatment Effect Waning in Immuno-oncology Health Technology Assessments: A Review of Assumptions and Supporting Evidence with Proposals to Guide Modelling
by Kurt Taylor & Nicholas R. Latimer & Thomas Douglas & Anthony J. Hatswell & Sophia Ho & Gabriel Okorogheye & John Borril & Clara Chen & Inkyu Kim & David Bertwistle - 1197-1208 Improving Transparency of Decision Models Through the Application of Decision Analytic Models with Omitted Objects Displayed (DAMWOOD)
by Jeff Round & Erin Kirwin & Sasha Katwyk & Christopher McCabe - 1209-1236 Rethinking Tuberculosis Morbidity Quantification: A Systematic Review and Critical Appraisal of TB Disability Weights in Cost-Effectiveness Analyses
by Ewan M. Tomeny & Thomas Hampton & Phuong Bich Tran & Laura Rosu & Mphatso D. Phiri & Kathryn A. Haigh & Jasper Nidoi & Tom Wingfield & Eve Worrall - 1237-1239 Delaying Oral Anticoagulants: A False Economy?
by Brendan Collins & Gregory Y. H. Lip - 1241-1253 Delay and Pay? Healthcare Costs Associated with Late Oral Anti-coagulant Prescribing in People with Atrial Fibrillation
by Ryan J. Mulholland & Giorgio Ciminata & Terry J. Quinn & Kevin G. Pollock & Steven Lister & Claudia Geue - 1255-1266 Empirical Testing of Alternative Search Methods to Retrieve Utility Values for Health Economic Modelling
by Johanna Lister & Suzy Paisley & Christopher Carroll & Paul Tappenden - 1267-1277 Considerations Around the Inclusion of Children and Young People’s Time in Economic Evaluation: Findings from an International Delphi Study
by Cameron Morgan & Cam Donaldson & Emily Lancsar & Stavros Petrou & Lazaros Andronis - 1279-1286 Drug Pricing Stewardship from Mark Cuban’s Cost Plus Generic Drug Program
by Snigdha Gulati & Mohak Gupta & TingTing Yan & Sneha Yelamanchili & Lucy Qinghua Xu & Tina Bharani & Ali Naji & Divyansh Agarwal - 1287-1300 Bring Out Your Dead: A Review of the Cost Minimisation Approach in Health Technology Assessment Submissions to the Australian Pharmaceutical Benefits Advisory Committee
by Zachary Tirrell & Alicia Norman & Martin Hoyle & Sean Lybrand & Bonny Parkinson
October 2024, Volume 42, Issue 10
- 1065-1072 Proxy Preferences and the Values of Children’s Health States
by Daniel M. Hausman - 1073-1090 Mixture and Non-mixture Cure Models for Health Technology Assessment: What You Need to Know
by Nicholas R. Latimer & Mark J. Rutherford - 1091-1110 Systematic Review of Economic Evaluations of Systemic Treatments for Advanced and Metastatic Gastric Cancer
by Shikha Sharma & Niamh Carey & David McConnell & Maeve Lowery & Jacintha O’Sullivan & Laura McCullagh - 1111-1125 Evaluating the Public Health and Health Economic Impacts of Baloxavir Marboxil and Oseltamivir for Influenza Pandemic Control in China: A Cost-Effectiveness Analysis Using a Linked Dynamic Transmission–Economic Evaluation Model
by Yawen Jiang & Jiaxin Wen & Jiatong Sun & Yuelong Shu - 1127-1144 Measuring the Direct Medical Costs of Hospital-Onset Infections Using an Analogy Costing Framework
by R. Douglas Scott & Steven D. Culler & James Baggs & Sujan C. Reddy & Kara Jacobs Slifka & Shelley S. Magill & Sophia V. Kazakova & John A. Jernigan & Richard E. Nelson & Robert E. Rosenman & Philip R. Wandschneider - 1145-1159 Unravelling Elements of Value of Healthcare and Assessing their Importance Using Evidence from Two Discrete-Choice Experiments in England
by Pamela Gongora-Salazar & Rafael Perera & Oliver Rivero-Arias & Apostolos Tsiachristas - 1161-1175 A Reporting Checklist for Discrete Choice Experiments in Health: The DIRECT Checklist
by Jemimah Ride & Ilias Goranitis & Yan Meng & Christine LaBond & Emily Lancsar
September 2024, Volume 42, Issue 9
- 913-917 NICE Approaches to Expert Opinion Evidence in Highly Specialised Technologies: Time to Change? Evidence Assessment Group Perspective
by Najmeh Moradi & Nicole O’Connor & Katie H. Thomson & Hosein Shabaninejad & Tumi Sotire & Madeleine Still & Cristina Fernandez-Garcia & Sheila A. Wallace & Oleta Williams & Luke Vale & Gurdeep S. Sagoo - 919-928 Rapid Assessment of the Need for Evidence: Applying the Principles of Value of Information to Research Prioritisation
by David Glynn & Vijay S. Gc & Karl Claxton & Chris Littlewood & Claire Rothery - 929-953 Evaluating the Cost-Utility of Continuous Glucose Monitoring in Individuals with Type 1 Diabetes: A Systematic Review of the Methods and Quality of Studies Using Decision Models or Empirical Data
by Lisa A. Jong & Xinyu Li & Sajad Emamipour & Sjoukje Werf & Maarten J. Postma & Peter R. Dijk & Talitha L. Feenstra - 955-1002 A Systematic Review of Modeling Approaches to Evaluate Treatments for Relapsed Refractory Multiple Myeloma: Critical Review and Considerations for Future Health Economic Models
by Andreas Freitag & Grammati Sarri & An Ta & Laura Gurskyte & Dasha Cherepanov & Luis G. Hernandez - 1003-1016 A Model-Based Economic Evaluation of Hypothetical Treatments for Amyotrophic Lateral Sclerosis in the UK: Implications for Pricing of New and Emerging Health Technologies
by Paul Tappenden & Orla Hardiman & Sun-Hong Kwon & Mon Mon-Yee & Miriam Galvin & Christopher McDermott - 1017-1028 Estimating Risk Factor Time Paths Among People with Type 2 Diabetes and QALY Gains from Risk Factor Management
by Ni Gao & Helen A. Dakin & Rury R. Holman & Lee-Ling Lim & José Leal & Philip Clarke - 1029-1045 Cost-Effectiveness of Plasma Microbial Cell-Free DNA Sequencing When Added to Usual Care Diagnostic Testing for Immunocompromised Host Pneumonia
by Andrew J. Sutton & Daniel S. Lupu & Stephen P. Bergin & Thomas L. Holland & Staci A. McAdams & Sanjeet S. Dadwal & Khoi Nguyen & Frederick S. Nolte & Gabriel Tremblay & Bradley A. Perkins - 1047-1063 Estimating an EQ-5D-Y-3L Value Set for Brazil
by Caique Melo Espirito Santo & Gisela Cristiane Miyamoto & Verônica Souza Santos & Ângela Jornada Ben & Aureliano Paolo Finch & Bram Roudijk & Fabianna Resende Jesus-Moraleida & Airton Tetelbom Stein & Marisa Santos & Tiê Parma Yamato
August 2024, Volume 42, Issue 8
- 823-827 Could or Should We Use Cost-Effectiveness Thresholds in the French Value-Based Pricing Process for New Drugs?
by Salah Ghabri - 829-832 Challenges in the Assessment of a Disease Model in the NICE Single Technology Appraisal of Tirzepatide for Treating Type 2 Diabetes: An External Assessment Group Perspective
by Mirre Scholte & Bram Ramaekers & Evangelos Danopoulos & Sabine E. Grimm & Andrea Fernandez Coves & Xiaoyu Tian & Thomas Debray & Jiongyu Chen & Lisa Stirk & Rachel Croft & Manuela Joore & Nigel Armstrong - 833-842 A Prototype Software Framework for Transferable Computational Health Economic Models and Its Early Application in Youth Mental Health
by Matthew P. Hamilton & Caroline Gao & Glen Wiesner & Kate M. Filia & Jana M. Menssink & Petra Plencnerova & David G. Baker & Patrick D. McGorry & Alexandra Parker & Jonathan Karnon & Sue M. Cotton & Cathrine Mihalopoulos - 843-863 A Systematic Review of Methods and Practice for Integrating Maternal, Fetal, and Child Health Outcomes, and Family Spillover Effects into Cost-Utility Analyses
by Ramesh Lamsal & E. Ann Yeh & Eleanor Pullenayegum & Wendy J. Ungar - 865-877 A Systematic Review of Methods for Estimating Productivity Losses due to Illness or Caregiving in Low- and Middle-Income Countries
by Ery Setiawan & Sarah A. Cassidy-Seyoum & Kamala Thriemer & Natalie Carvalho & Angela Devine - 879-894 Examining the Effect of Depicting a Patient Affected by a Negative Reimbursement Decision in Healthcare on Public Disagreement with the Decision
by Anne Bruijn & Mats Don & Saskia Knies & Werner Brouwer & Vivian Reckers-Droog - 895-909 Understanding Clinician Preferences for Treatment Attributes in Oncology: A Discrete Choice Experiment of Oncologists’ and Urologists’ Preferences for First-Line Treatment of Locally Advanced/Unresectable Metastatic Urothelial Carcinoma in Five European Countries
by Laura Panattoni & Mairead Kearney & Natalie Land & Thomas Flottemesch & Patrick Sullivan & Melissa Kirker & Murtuza Bharmal & Brett Hauber - 911-911 Correction to: Understanding Clinician Preferences for Treatment Attributes in Oncology: A Discrete Choice Experiment of Oncologists’ and Urologists’ Preferences for First-Line Treatment of Locally Advanced/Unresectable Metastatic Urothelial Carcinoma in Five European Countries
by Laura Panattoni & Mairead Kearney & Natalie Land & Thomas Flottemesch & Patrick Sullivan & Melissa Kirker & Murtuza Bharmal & Brett Hauber
July 2024, Volume 42, Issue 7
- 715-719 Evaluating the Validation Process: Embracing Complexity and Transparency in Health Economic Modelling
by Isaac Corro Ramos & Talitha Feenstra & Salah Ghabri & Maiwenn Al - 721-735 Bayesian Meta-Analysis of Health State Utility Values: A Tutorial with a Practical Application in Heart Failure
by Joseph Alvin Ramos Santos & Robert Grant & Gian Luca Di Tanna - 737-749 Advances in Addressing Patient Heterogeneity in Economic Evaluation: A Review of the Methods Literature
by Gemma E. Shields & Paul Clarkson & Ash Bullement & Warren Stevens & Mark Wilberforce & Tracey Farragher & Arpana Verma & Linda M. Davies - 751-765 Cost-of-Illness of Skin Cancer: A Systematic Review
by Annick Meertens & Laura Coile & Tijs Iseghem & Lieve Brochez & Nick Verhaeghe & Isabelle Hoorens - 767-782 Quality Appraisal in Systematic Literature Reviews of Studies Eliciting Health State Utility Values: Conceptual Considerations
by Muchandifunga Trust Muchadeyi & Karla Hernandez-Villafuerte & Gian Luca Tanna & Rachel D. Eckford & Yan Feng & Michela Meregaglia & Tessa Peasgood & Stavros Petrou & Jasper Ubels & Michael Schlander - 783-795 Barriers and Facilitators of Using R for Decision Analytic Modeling in Health Technology Assessment: Focus Group Results
by Yanara Marks & Jeffrey S. Hoch & Anna Heath & Petros Pechlivanoglou - 797-810 A Blueprint for Multi-use Disease Modeling in Health Economics: Results from Two Expert-Panel Consultations
by Junfeng Wang & Xavier Pouwels & Bram Ramaekers & Geert Frederix & Chris Lieshout & Rudolf Hoogenveen & Xinyu Li & G. Ardine Wit & Manuela Joore & Hendrik Koffijberg & Anoukh Giessen & Saskia Knies & Talitha Feenstra - 811-822 Cost Effectiveness of Fremanezumab in Episodic and Chronic Migraine Patients from a Japanese Healthcare Perspective
by Takao Takeshima & Fumihiko Sakai & Xinyu Wang & Kentaro Yamato & Yoshitsugu Kojima & Yilong Zhang & Craig Bennison & Martijn J. H. G. Simons
June 2024, Volume 42, Issue 6
- 611-614 Market Transparency in Medicine Pricing: Pathways to Fair Pricing
by João L. Carapinha - 615-618 Bayesian Hierarchical Modelling for Histology-Independent Time-to-Event Outcomes in the NICE Single Technology Appraisal of Pembrolizumab for Solid Tumours with MSI-H/dMMR: External Assessment Group Perspective
by Bradley M. Sugden & Sabine E. Grimm & Robert Wolff & Nigel Armstrong & Thomas Otten & Teebah Abu-Zahra & Mark Perry & Mubarak Patel & Jiongyu Chen & Caro Noake & Manuela Joore & Willem J. A. Witlox - 619-631 Issues, Challenges and Opportunities for Economic Evaluations of Orphan Drugs in Rare Diseases: An Umbrella Review
by Tobias Sydendal Grand & Shijie Ren & James Hall & Daniel Oudin Åström & Stephane Regnier & Praveen Thokala - 633-647 Lessons Learned from Model-based Economic Evaluations of COVID-19 Drug Treatments Under Pandemic Circumstances: Results from a Systematic Review
by Clazinus Veijer & Marinus H. Hulst & Benjamin Friedrichson & Maarten J. Postma & Antoinette D.I. Asselt - 649-661 Childhood Transitions Between Weight Status Categories: Evidence from the UK Millennium Cohort Study
by Olu Onyimadu & Nerys M. Astbury & Felix Achana & Stavros Petrou & Mara Violato - 663-678 Developing a Program Costs Checklist of Digital Health Interventions: A Scoping Review and Empirical Case Study
by Zareen Abbas Khan & Kristian Kidholm & Sindre Andre Pedersen & Silje Marie Haga & Filip Drozd & Thea Sundrehagen & Ellen Olavesen & Vidar Halsteinli - 679-691 Is Risk-Stratifying Patients with Colorectal Cancer Using a Deep Learning-Based Prognostic Biomarker Cost-Effective?
by Anna Kenseth & Dominika Kantorova & Mikyung Kelly Seo & Eline Aas & John Cairns & David Kerr & Hanne Askautrud & Jørn Evert Jacobsen - 693-714 Cost-Effectiveness of Lovotibeglogene Autotemcel (Lovo-Cel) Gene Therapy for Patients with Sickle Cell Disease and Recurrent Vaso-Occlusive Events in the United States
by William L. Herring & Meghan E. Gallagher & Nirmish Shah & KC Morse & Deirdre Mladsi & Olivia M. Dong & Anjulika Chawla & Jennifer W. Leiding & Lixin Zhang & Clark Paramore & Biree Andemariam
May 2024, Volume 42, Issue 5
- 475-478 Economic Evaluations of Treatments for Duchenne Muscular Dystrophy: The Caregiver QALY Trap
by Erik Landfeldt & Hera Sandhu - 479-486 Value of Information for Clinical Trial Design: The Importance of Considering All Relevant Comparators
by Anna Heath & Gianluca Baio & Ioanna Manolopoulou & Nicky J. Welton - 487-506 Challenges and Opportunities in Interdisciplinary Research and Real-World Data for Treatment Sequences in Health Technology Assessments
by Jen-Yu Amy Chang & James B. Chilcott & Nicholas R. Latimer - 507-526 Content Comparison of Quality-of-Life Instruments Used in Economic Evaluations of Sleep Disorder Interventions: A Systematic Review
by Billingsley Kaambwa & Taylor-Jade Woods & Andrea Natsky & Norma Bulamu & Christine Mpundu-Kaambwa & Kelly A. Loffler & Alexander Sweetman & Peter G. Catcheside & Amy C. Reynolds & Robert Adams & Danny J. Eckert - 527-568 Critical Examination of Modeling Approaches Used in Economic Evaluations of First-Line Treatments for Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations: A Systematic Literature Review
by Angie Raad & Maria Rizzo & Katherine Appiah & Isabella Kearns & Luis Hernandez - 569-582 Budget Impact of Introducing Fixed-Duration Mosunetuzumab for the Treatment of Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy in the USA
by Shih-Wen Lin & Sheila Shapouri & Hélène Parisé & Eric Bercaw & Mei Wu & Eunice Kim & Matthew Matasar - 583-603 Population Norms for the EQ-5D-5L, PROPr and SF-6D in Hungary
by Anna Nikl & Mathieu F. Janssen & Balázs Jenei & Valentin Brodszky & Fanni Rencz - 605-606 Comment on: A Framework for the Fair Pricing of Medicines
by Zaheer-Ud-Din Babar - 607-609 Reply to Comment on “A Framework for Fair Pricing of Medicines”
by Mike Paulden
April 2024, Volume 42, Issue 4
- 363-371 A Guide to an Iterative Approach to Model-Based Decision Making in Health and Medicine: An Iterative Decision-Making Framework
by Natalia Kunst & Emily A. Burger & Veerle M. H. Coupé & Karen M. Kuntz & Eline Aas - 373-392 Cost-Effectiveness of Screening Strategies for Familial Hypercholesterolaemia: An Updated Systematic Review
by Clara Marquina & Jedidiah I Morton & Melanie Lloyd & Dina Abushanab & Yeji Baek & Tamrat Abebe & Adam Livori & Padam Dahal & Gerald F. Watts & Zanfina Ademi - 393-407 An Exploratory Analysis of the Cost-Effectiveness of a Multi-cancer Early Detection Blood Test Compared with Standard of Care Screening in Ontario, Canada
by Diedron Lewis & William W. L. Wong & Joseph Lipscomb & Susan Horton - 409-418 Cost Effectiveness of Zanubrutinib Versus Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
by Dong-Won Kang & Li Wang & Nicholas J. Short & Alessandra Ferrajoli & Yucai Wang & Shouhao Zhou & Chan Shen - 419-434 Exploring the Cost Effectiveness of a Whole-Genome Sequencing-Based Biomarker for Treatment Selection in Patients with Advanced Lung Cancer Ineligible for Targeted Therapy
by Zakile A. Mfumbilwa & Martijn J. H. G. Simons & Bram Ramaekers & Valesca P. Retèl & Joanne M. Mankor & Harry J. M. Groen & Joachim G. J. V. Aerts & Manuela Joore & Janneke A. Wilschut & Veerle M. H. Coupé - 435-446 The RETRIEVE Checklist for Studies Reporting the Elicitation of Stated Preferences for Child Health-Related Quality of Life
by Cate Bailey & Martin Howell & Rakhee Raghunandan & Kim Dalziel & Kirsten Howard & Brendan Mulhern & Stavros Petrou & Donna Rowen & Amber Salisbury & Rosalie Viney & Emily Lancsar & Nancy Devlin - 447-461 Cost-effectiveness of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United States
by Anita J. Brogan & Ashley E. Davis & Claire E. Mellott & Jeremy Fraysse & Aimee A. Metzner & Alan K. Oglesby - 463-473 The Burden of Type 2 Diabetes on the Productivity and Economy in Sub-Saharan Africa: A Life Table Modelling Analysis from a South African Perspective
by Assegid Hellebo & Andre P. Kengne & Zanfina Ademi & Olufunke Alaba
March 2024, Volume 42, Issue 3
- 249-252 Making Decision Models Fit for Purpose: The Importance of Ensuring Stakeholder Involvement
by Stephanie Harvard - 253-259 A Research Framework to Improve Health Disparity Evidence Gaps in Value Assessments
by T. Joseph Mattingly - 261-273 Estimating Costs Associated with Disease Model States Using Generalized Linear Models: A Tutorial
by Junwen Zhou & Claire Williams & Mi Jun Keng & Runguo Wu & Borislava Mihaylova - 275-299 Evaluating the Quantity and Quality of Health Economic Literature in Blinding Childhood Disorders: A Systematic Literature Review
by Lucinda J. Teoh & Salomey Kellett & Dipesh E. Patel & Mario Cortina-Borja & Ameenat Lola Solebo & Jugnoo S. Rahi - 301-318 Palliative Care Costs in Different Ambulatory-Based Settings: A Systematic Review
by Ana Helena Perea-Bello & Marta Trapero-Bertran & Christian Dürsteler - 319-328 Using Real-World Data to Inform Value-Based Contracts for Cell and Gene Therapies in Medicaid
by Antal Zemplenyi & Jim Leonard & Michael J. DiStefano & Kelly E. Anderson & Garth C. Wright & Nicholas D. Mendola & Kavita Nair & R. Brett McQueen - 329-341 Estimating the Treatment and Prophylactic Economic Value of New Antimicrobials in Managing Antibiotic Resistance and Serious Infections for Common Pathogens in the USA: A Population Modelling Study
by Jason Gordon & Maria Gheorghe & Cale Harrison & Ryan Miller & James Dennis & Lotte Steuten & Simon Goldenberg & Sumanth Gandra & Amer Al-Taie - 343-362 Recommendations for Emerging Good Practice and Future Research in Relation to Family and Caregiver Health Spillovers in Health Economic Evaluations: A Report of the SHEER Task Force
by Edward Henry & Hareth Al-Janabi & Werner Brouwer & John Cullinan & Lidia Engel & Susan Griffin & Claire Hulme & Pritaporn Kingkaew & Andrew Lloyd & Nalin Payakachat & Becky Pennington & Luz María Peña-Longobardo & Lisa A. Prosser & Koonal Shah & Wendy J. Ungar & Thomas Wilkinson & Eve Wittenberg
February 2024, Volume 42, Issue 2
- 133-136 Considerations for the Cure Assumption in an NICE Single Technology Appraisal of Nivolumab with Chemotherapy for Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer: Evidence Assessment Group Perspective
by Giovany Orozco-Leal & Eugenie Evelynne Johnson & Sedighe Hosseinijebeli & Tomos Robinson & Tara Homer & Claire H. Eastaugh & Catherine Richmond & Louise Tanner & Nick Meader & Ryan Kenny & Sheila A. Wallace & Stephen Rice - 137-144 Surrogacy and the Valuation of ATMPs: Taking Our Place in the Evidence Generation/Assessment Continuum
by Daniel Gladwell & Oriana Ciani & Adam Parnaby & Stephen Palmer - 145-164 A Framework for the Fair Pricing of Medicines
by Mike Paulden - 165-176 Transporting Comparative Effectiveness Evidence Between Countries: Considerations for Health Technology Assessments
by Alex J. Turner & Cormac Sammon & Nick Latimer & Blythe Adamson & Brennan Beal & Vivek Subbiah & Keith R. Abrams & Joshua Ray - 177-198 Systematic Review of the Relative Social Value of Child and Adult Health
by Tessa Peasgood & Martin Howell & Rakhee Raghunandan & Amber Salisbury & Marcus Sellars & Gang Chen & Joanna Coast & Jonathan C. Craig & Nancy J. Devlin & Kirsten Howard & Emily Lancsar & Stavros Petrou & Julie Ratcliffe & Rosalie Viney & Germaine Wong & Richard Norman & Cam Donaldson - 199-217 A Systematic Review of Methods Used by Pediatric Cost-Utility Analyses to Include Family Spillover Effects
by Ramesh Lamsal & E. Ann Yeh & Eleanor Pullenayegum & Wendy J. Ungar - 219-229 Cost-Effectiveness Analysis of Vaccines for COVID-19 According to Sex, Comorbidity and Socioeconomic Status: A Population Study
by Javier Mar & Oliver Ibarrondo & Carlo Delfin S. Estadilla & Nico Stollenwerk & Fernando Antoñanzas & Rubén Blasco-Aguado & Igor Larrañaga & Joseba Bidaurrazaga & Maíra Aguiar - 231-247 Cost-Effectiveness Modeling of Prostate-Specific Membrane Antigen Positron Emission Tomography with Piflufolastat F 18 for the Initial Diagnosis of Patients with Prostate Cancer in the United States
by Christopher W. Yee & Michael J. Harvey & Yiqiao Xin & Noam Y. Kirson
July 2024, Volume 42, Issue 2
- 183-185 Advancing Methods to Measure and Reward Healthcare Innovation
by Richard Chapman & Richard Xie - 187-197 The Value of Flexible Vaccine Manufacturing Capacity: Value Drivers, Estimation Methods, and Approaches to Value Recognition in Health Technology Assessment
by Frederick McElwee & Anthony Newall - 199-210 Incorporating Real Option Value in Valuing Innovation: A Way Forward
by Meng Li & Louis P. Garrison - 211-224 Estimating and Rewarding the Value of Healthcare Interventions Beyond the Healthcare Sector: A Conceptual Framework
by Askal Ayalew Ali & Amit Kulkarni & Sandipan Bhattacharjee & Vakaramoko Diaby
January 2024, Volume 42, Issue 1
- 5-9 Disease Severity Modifier in the NICE Single Technology Appraisal of Trastuzumab Deruxtecan: External Assessment Group Perspective
by Diarmuid Coughlan & Oluwatomi Arisa & Katie Thomson & Ge Yu & Fiona Pearson & Ashleigh Kernohan & Sonia Garcia Gonzalez-Moral & Sheila Wallace & Stephen Rice - 11-18 The Difference Method Approach for Sampling Order Constrained Parameters: An Improved Implementation and Important Limitations
by Daniel Hill-McManus - 19-40 A Systematic Review of Methodologies Used in Models of the Treatment of Diabetes Mellitus
by Marina Antoniou & Céu Mateus & Bruce Hollingsworth & Andrew Titman - 41-68 Economic Evaluations Comparing Deep Brain Stimulation to Best Medical Therapy for Movement Disorders: A Meta-Analysis
by Melissa Lannon & Taylor Duda & Alexander Mastrolonardo & Ellissa Huang & Amanda Martyniuk & Forough Farrokhyar & Feng Xie & Mohit Bhandari & Suneil K. Kalia & Sunjay Sharma - 69-90 Cost-Effectiveness Analysis of Pharmacogenomics (PGx)-Based Warfarin, Apixaban, and Rivaroxaban Versus Standard Warfarin for the Management of Atrial Fibrillation in Ontario, Canada
by Aneeka Hafeez & Lauren E. Cipriano & Richard B. Kim & Gregory S. Zaric & Ute I. Schwarz & Sisira Sarma - 91-107 Lipid-Lowering Strategies for Primary Prevention of Coronary Heart Disease in the UK: A Cost-Effectiveness Analysis
by Jedidiah I. Morton & Clara Marquina & Melanie Lloyd & Gerald F. Watts & Sophia Zoungas & Danny Liew & Zanfina Ademi - 109-116 Modelling Health State Utilities as a Transformation of Time to Death in Patients with Non-Small Cell Lung Cancer
by Anthony J. Hatswell & Mohammad A. Chaudhary & Giles Monnickendam & Alejandro Moreno-Koehler & Katie Frampton & James W. Shaw & John R. Penrod & Rachael Lawrance - 117-131 Launch and Post-Launch Prices of Injectable Cancer Drugs in the US: Clinical Benefit, Innovation, Epidemiology, and Competition
by Daniel Tobias Michaeli & Thomas Michaeli
June 2024, Volume 42, Issue 1
- 3-8 Meeting the Challenges of Preference-Weighted Health-Related Quality-of-Life Measurement in Children
by Wendy J. Ungar & Michael Herdman - 9-37 Exploring the Use of Pictorial Approaches in the Development of Paediatric Patient-Reported Outcome Instruments: A Systematic Review
by Christine Mpundu-Kaambwa & Norma B. Bulamu & Lauren Lines & Gang Chen & David G. T. Whitehurst & Kim Dalziel & Nancy Devlin & Julie Ratcliffe - 39-55 Comparative Psychometric Performance of Common Generic Paediatric Health-Related Quality of Life Instrument Descriptive Systems: Results from the Australian Paediatric Multi-Instrument Comparison Study
by Renee Jones & Rachel O’Loughlin & Xiuqin Xiong & Mina Bahrampour & Nancy Devlin & Harriet Hiscock & Gang Chen & Brendan Mulhern & Kim Dalziel - 57-77 Comparing the Psychometric Performance of Generic Paediatric Health-Related Quality of Life Instruments in Children and Adolescents with ADHD, Anxiety and/or Depression
by Rachel O’Loughlin & Renee Jones & Gang Chen & Brendan Mulhern & Harriet Hiscock & Nancy Devlin & Kim Dalziel - 79-79 Correction: Comparing the Psychometric Performance of Generic Paediatric Health‑Related Quality of Life Instruments in Children and Adolescents with ADHD, Anxiety and/or Depression
by Rachel O’Loughlin & Renee Jones & Gang Chen & Brendan Mulhern & Harriet Hiscock & Nancy Devlin & Kim Dalziel - 81-94 Comparing Generic Paediatric Health-Related Quality-of-Life Instruments: A Dimensionality Assessment Using Factor Analysis
by Mina Bahrampour & Renee Jones & Kim Dalziel & Nancy Devlin & Brendan Mulhern - 95-111 A Comparison of the Psychometric Properties of the EQ-5D-Y-3L and EQ-5D-Y-5L Using Paediatric Multi-Instrument Comparison (P-MIC) Study Data
by Mina Bahrampour & Nancy Devlin & Renee Jones & Kim Dalziel & Brendan Mulhern - 113-128 An Investigation of Inter-Rater and Intra-Proxy Agreement in Measuring Quality of Life of Children in the Community Using the EQ-5D-Y-3L
by Diana Khanna & Jyoti Khadka & Christine Mpundu-Kaambwa & Gang Chen & Kim Dalziel & Nancy Devlin & Julie Ratcliffe - 129-145 Psychometric Performance Comparison of the Adapted versus Original Versions of the EQ-5D-Y-3L and -Y-5L in Proxy Respondents for 2- to 4-Year-Olds
by Alexander Heusden & Oliver Rivero-Arias & Michael Herdman & Harriet Hiscock & Nancy Devlin & Kim Dalziel - 147-161 Psychometric Properties of Child Health Utility 9D (CHU9D) Proxy Version Administered to Parents and Caregivers of Children Aged 2–4 Years Compared with Pediatric Quality of Life Inventory™ (PedsQL)
by Xiuqin Xiong & Natalie Carvalho & Li Huang & Gang Chen & Renee Jones & Nancy Devlin & Brendan Mulhern & Kim Dalziel - 163-179 The Validity of the EuroQol Health and Wellbeing Short Version (EQ-HWB-S) Instrument in Parents of Children With and Without Health Conditions
by Cate Bailey & Kim Dalziel & Renee Jones & Harriet Hiscock & Nancy J. Devlin & Tessa Peasgood
December 2023, Volume 41, Issue 12
- 1553-1555 The Carer QALY Trap and Altruism in Economic Evaluations
by J. Mick Tilford & Aygul Tarlan - 1557-1561 Modelling Spillover Effects on Informal Carers: The Carer QALY Trap
by David J. Mott & Hannah Schirrmacher & Hareth Al-Janabi & Sophie Guest & Becky Pennington & Nicolas Scheuer & Koonal K. Shah & Chris Skedgel